Agenus | AGEN - Current Liabilities


Agenus reported $287.13M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Agenus USD 287.13M 52.57M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Celldex Therapeutics USD 46.46M 13.5M Sep/2025
CSL USD 4.82B 1.26B Jun/2025
Dynavax Technologies USD 106.84M 11.39M Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
Intrexon USD 23.02M 38K Jun/2024
J&J USD 54.13B 3.26B Dec/2025
Jiangsu Hengrui CNY 7.85B 4.39B Sep/2025
Karyopharm Therapeutics USD 87.16M 12.06M Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Merck EUR 8.64B 1.22B Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Novartis USD 32B 286M Sep/2025
Novavax USD 429.87M 40.73M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Veracyte USD 72.15M 4.28M Sep/2025